Income StatementBalance SheetCash FlowSegments
Gilead Sciences logo

Gilead Sciences Business Segments

Business, geographic, and product segment breakdowns

Gilead Sciences generates $29.7B in annual revenue across 4 key segments: AmBisome ($508.0M), Biktarvy ($14.5B), Descovy ($3.0B), and Genvoya ($1.4B). The company-wide operating margin is 34.88%. Based on the Q1 2026 filing.

AmBisome (TTM)$508.0MBiktarvy (TTM)$14.5BDescovy (TTM)$3.0BGenvoya (TTM)$1.4BLivdelzi$133.0MOdefsey (TTM)$1.1BOther HIV (TTM)$482.0MOther Liver Disease (TTM)$827.0M
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$166.82B
P/E Ratio18.10
ROE43.19%

Products & Services

Total revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Biktarvy$3.8B$3.2B$3.5B$3.7B$4.0B$3.4B
Descovy$617.0M$586.0M$653.0M$701.0M$819.0M$807.0M
Trodelvy$355.0M$293.0M$364.0M$357.0M$384.0M$402.0M
Yescarta$389.0M$386.0M$393.0M$349.0M$368.0M$332.0M
Sofosbuvir/Velpatasvir$330.0M$346.0M$342.0M$309.0M$276.0M$283.0M
Genvoya$470.0M$364.0M$377.0M$377.0M$380.0M$264.0M
Vemlidy$260.0M$252.0M$252.0M$280.0M$287.0M$237.0M
Odefsey$336.0M$281.0M$298.0M$277.0M$310.0M$221.0M
Yeztugo—$0.0———$166.0M
Veklury$338.0M$302.0M$121.0M$277.0M$211.0M$144.0M
AmBisome$109.0M$139.0M$129.0M$123.0M$118.0M$138.0M
Symtuza - Revenue share$144.0M$114.0M$124.0M$124.0M$133.0M$138.0M
Livdelzi—$40.0M———$133.0M
Other Liver Disease$130.0M$121.0M$201.0M$231.0M$281.0M$114.0M
Tecartus$98.0M$78.0M$92.0M$83.0M$90.0M$75.0M
Other HIV$112.0M$91.0M$107.0M$112.0M$190.0M$73.0M
Other$75.0M$70.0M$73.0M$61.0M$86.0M$58.0M
Royalty, contract and other revenues$33.0M$54.0M$27.0M$424.0M$22.0M$14.0M

Percentage of revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Product7.2%7.2%7.2%7.2%7.2%—

Geographic

Total revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
U.S.$5.6B$4.7B$5.1B$5.3B$5.9B$4.9B
Europe$1.2B$1.1B$1.2B$1.6B$1.2B$1.1B
Rest of World$826.0M$915.0M$842.0M$933.0M$813.0M$889.0M

Property, plant and equipment, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
U.S.$4.8B———$5.0B—

Business Segments

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Selling, general and administrative expenses$1.9B$1.3B$1.4B$1.4B$1.8B$1.5B
Selling and marketing expenses$1.1B$753.0M$864.0M$829.0M$1.1B$898.0M
General and administrative expenses$850.0M$505.0M$501.0M$527.0M$718.0M$553.0M